Owner of Johnson & Johnson: JNJ holds a prominent place in the American multinational corporation. With a storied history dating back to its founding in 1886 by three visionary brothers: Robert, James, and Edward Johnson.
Over the years, the company has emerged as a pioneer in the healthcare sector. The Company is known for its innovative products that have positively impacted countless lives. Today, J&J is a publicly traded company, with its ownership dispersed among various shareholders.
Company Details: Owner of Johnson & Johnson
|Johnson & Johnson
|Robert Wood Johnson I
James Wood Johnson
Edward Mead Johnson
|Johnson and Johnson Plaza in New Brunswick,
|Johnson & Johnson
Major Milestones and Controversies from 2000 to Present
From 2000 to the present, Johnson & Johnson has undergone significant developments and acquisitions across various sectors. The company launched products like Vicryl Plus Antibacterial Sutures in 2003.
In 2006, J&J acquired Pfizer’s consumer healthcare business, expanding its portfolio to include brands like Listerine and Neosporin. The company also made key acquisitions in medical technologies and pharmaceutical therapies. During the COVID-19 pandemic, J&J committed over $1 billion to develop a not-for-profit COVID-19 vaccine.
However, the company has faced criticism for its patent practices, particularly with regard to the tuberculosis-treating drug bedaquiline, which has led to advocacy for the patent’s expiration to improve accessibility to the treatment.
Who is the Owner of Johnson & Johnson
There is no single individual owner or family that possesses outright control of Johnson & Johnson. Instead, the company’s ownership is dispersed among the multitude of investors who have invested in its stock through the public markets.
A wide array of stakeholders, including institutional investors, mutual funds, individual shareholders, and insiders, actively own the distribution of ownership.
|Joseph J. Wolk
Alex Gorsky: The Visionary Executive Chairman
Among the key shareholders of Johnson & Johnson is Alex Gorsky, the company’s Executive Chairman. With an impressive background, Gorsky joined JNJ as a sales representative in 1988, ascending through the ranks to hold pivotal positions.
In 2012, the board appointed him as the CEO and Chair, and he spearheaded the company’s strategic growth. As of February 2021, Gorsky owns 3.2 million shares, making him the largest individual shareholder.
Joaquin Duato: The CEO with Decades of Dedication
As of 2023, Joaquin Duato serves is the Chief Executive Officer and Chairman of Johnson & Johnson, and he is the second-largest individual shareholder with 1,041,512 shares as of February 2021. Duato’s loyalty to the company spans almost three decades, reflecting his unwavering commitment to driving the organization forward with innovative solutions and patient-centric care.
Paulus Stoffels: A Scientific Visionary
Paulus Stoffels, Ph.D., is a pivotal figure in Johnson & Johnson’s success. As the third-largest individual shareholder with 871,800 shares, Stoffels previously served as JNJ’s Chief Scientific Officer and Executive Vice President. His exceptional expertise in infectious disease treatment and tropical diseases has been instrumental in driving the company’s research and development efforts.
Jennifer Taubert: A Leader in Pharmaceuticals
Jennifer Taubert is the fourth-largest individual shareholder of JNJ, holding just over 453,000 shares. As the Worldwide Chair of JNJ’s Pharmaceuticals, Taubert leads the Pharmaceuticals Group Operating Committee, making significant contributions to the fight against diseases such as HIV, cancer, heart disease, diabetes, and mental illness.
Joseph J. Wolk: The CFO Driving Financial Strategy
As the Executive Vice President and Chief Financial Officer (CFO) of Johnson & Johnson, Joseph J. Wolk plays a crucial role in shaping the company’s financial strategy. Holding almost 101,000 shares, Wolk’s nearly 23-year tenure with JNJ has seen him lead global financial initiatives and build strong relationships with investors.
Johnson & Johnson Subsidiaries
- DePuy Synthes
- Janssen Biotech
- Janssen Pharmaceuticals
- Janssen Vaccines
- J&J Vision
Services Provided by J&J
With a strong commitment to improving lives through innovative products and cutting-edge technologies, J&J plays a significant role in the consumer health, medical technologies, and pharmaceutical therapies sectors. Let’s explore the company’s contributions and major franchises in each of these areas.
The consumer health sector offers various products for personal healthcare, such as skin health, beauty, over-the-counter medicines, baby care, oral care, women’s health, and wound care.
In medical technologies, J&J’s key areas are interventional solutions, orthopedics, surgery, and vision.
The pharmaceutical therapies segment includes major franchises in immunology, neuroscience, infectious disease and vaccines, oncology, cardiovascular and metabolism, and pulmonary hypertension.
A Legacy of Innovation and Resilience
Despite facing legal challenges, Johnson & Johnson remains steadfast in its mission of advancing healthcare worldwide. The company’s pioneering spirit has led to groundbreaking innovations, notably the development of a single-shot COVID-19 vaccine.
Throughout its long history, the owners and shareholders of Johnson & Johnson have played a vital role in driving innovation, upholding its reputation as a trusted leader in the healthcare industry. As the company continues to evolve and address emerging challenges, its vision and dedication remain central to its ongoing success.
Note: It is important to keep in mind that ownership information is subject to change due to fluctuations in stock ownership and trading activity.
Alex Gorsky is the Owner of Johnson & Johnson as he owns the largest number of shares in the company.